Stifel Initiates Coverage On Lexeo Therapeutics with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has initiated coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and set a price target of $20.
November 28, 2023 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Paul Matteis has initiated coverage on Lexeo Therapeutics with a Buy rating and a price target of $20.
Initiation of coverage by an analyst with a Buy rating typically generates positive sentiment among investors, potentially driving the stock price up in the short term. The price target of $20 suggests a significant upside from the current trading level, assuming the stock is below this target, which could lead to increased investor interest and buying activity.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100